Currently President of the European Organization for Research and Treatment of Cancer (EORTC), Prof Stupp has contributed to an important practice change in the neuro-oncology filed, introducing novel chemotherapeutics.

He has been lead investigator on several academic large phase III trials and is closely involved in bringing new anti-angiogenic and biological treatments to the clinic.

He is Professor at the University of Zurich, Switzerland, Chair and Director of the Department of Oncology of the University Hospital Zurich and the Zurich Cancer Centre.

He is serving as expert in the ESMO Faculty groups for Central Nervous System tumours and Principles of Clinical Trials and Systemic Therapy and is past secretary of the EORTC Brain Tumour Group.

Josep Tabernero said: “Roger Stupp has played a critical role in establishing the bench-bedside-bench virtuous cycle of knowledge throughout Europe to dramatically improve the clinical management and outcome of patients in daily practice.”

Receiving the award, Prof Stupp said: “This recognition of my peers emphasizes the importance of clinical investigators in a healthcare environment that is notoriously short of resources, overburdened with regulations and facing increasing costs for marginal improvements.

Research is never performed by one person alone and as such one receives an award as a representative of innumerable people.” Acknowledging the support of friends and colleagues, he added: “Most importantly, I would like to mention the patients who trust us and participate in clinical and translational trials.”

“This award is recognition for past contributions and, more importantly, an obligation to continue in the quest for better understanding of cancer and more efficient treatments for our patients,” Prof Stupp said.

Source: ESMO